Perspective Therapeutics (CATX) Stock Forecast, Price Target & Predictions
CATX Stock Forecast
Perspective Therapeutics stock forecast is as follows: an average price target of $18.00 (represents a 165.49% upside from CATX’s last price of $6.78) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
CATX Price Target
CATX Analyst Ratings
Buy
Perspective Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 24, 2024 | David Dai | UBS | $20.00 | $11.69 | 71.09% | 194.99% |
Oct 14, 2024 | Jeff Jones | Oppenheimer | $22.00 | $12.66 | 73.78% | 224.48% |
Sep 25, 2024 | Nicole Germino | Truist Financial | $21.00 | $12.28 | 71.01% | 209.73% |
Jul 25, 2024 | Alec Stranahan | Bank of America Securities | $24.00 | $12.82 | 87.21% | 253.98% |
Jun 18, 2024 | Jeff Jones | Oppenheimer | $19.00 | $11.93 | 59.26% | 180.24% |
Jun 14, 2024 | Gregory Renza | RBC Capital | $3.00 | $1.15 | 161.21% | -55.75% |
May 15, 2024 | Jeff Jones | Oppenheimer | $2.00 | $1.57 | 27.39% | -70.50% |
10
Perspective Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 3 | 7 |
Avg Price Target | $20.00 | $21.00 | $15.86 |
Last Closing Price | $6.78 | $6.78 | $6.78 |
Upside/Downside | 194.99% | 209.73% | 133.92% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 24, 2024 | UBS | - | Buy | Initialise |
Oct 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Sep 30, 2024 | Wedbush | - | Outperform | Initialise |
Jun 18, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Jun 14, 2024 | RBC Capital | Outperform | Outperform | Hold |
May 15, 2024 | Oppenheimer | Outperform | Outperform | Hold |
May 14, 2024 | RBC Capital | - | Outperform | Initialise |
May 09, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
Apr 09, 2024 | B. Riley | Buy | Buy | Hold |
Apr 01, 2024 | Oppenheimer | Outperform | Outperform | Hold |
10
Perspective Therapeutics Financial Forecast
Perspective Therapeutics Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.50M | $1.83M | $1.83M | $1.72M | $2.50M | $2.91M | $2.82M | $2.56M | $2.71M | $2.60M | $2.36M | $2.38M | $2.28M | $2.88M | $2.21M |
Avg Forecast | $2.06M | $2.05M | $2.03M | $2.02M | $100.80K | $99.80K | $98.81K | $147.83K | $308.62K | $292.76K | $183.48K | $368.80K | $1.85M | $2.60M | $2.06M | $2.84M | $2.84M | $2.95M | $2.49M | $2.70M | $2.43M | $2.40M | $2.85M | $2.70M | $2.54M | $2.30M | $2.12M | $1.93M | $1.93M |
High Forecast | $3.03M | $3.01M | $2.99M | $2.98M | $148.23K | $146.76K | $145.31K | $149.58K | $453.86K | $430.53K | $183.72K | $368.90K | $2.23M | $3.82M | $3.03M | $4.18M | $2.98M | $2.95M | $2.49M | $2.70M | $2.43M | $2.40M | $2.85M | $2.70M | $2.54M | $2.30M | $2.12M | $1.93M | $1.97M |
Low Forecast | $1.06M | $1.05M | $1.05M | $1.04M | $51.88K | $51.37K | $50.86K | $146.08K | $158.85K | $150.69K | $183.24K | $368.70K | $1.47M | $1.34M | $1.06M | $1.46M | $2.71M | $2.95M | $2.49M | $2.70M | $2.43M | $2.40M | $2.85M | $2.70M | $2.54M | $2.30M | $2.12M | $1.93M | $1.89M |
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.73% | 0.64% | 0.65% | 0.58% | 1.01% | 1.08% | 1.16% | 1.07% | 0.95% | 0.96% | 0.93% | 1.04% | 1.08% | 1.49% | 1.14% |
Forecast
Perspective Therapeutics EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-11.08M | $-10.65M | $-3.10M | $-4.21M | $-2.11M | $-1.38M | $-1.64M | $-2.21M | $-1.09M | $-762.00K | $-859.00K | $-714.00K | $-1.19M | $-512.00K | $-864.00K |
Avg Forecast | $-1.28M | $-1.27M | $-1.27M | $-1.26M | $-62.69K | $-62.07K | $-61.45K | $-91.94K | $-191.94K | $-182.08K | $-114.11K | $-229.37K | $-1.15M | $-1.62M | $-1.28M | $-1.77M | $-1.77M | $-1.83M | $-1.55M | $-1.68M | $-1.51M | $-1.49M | $-1.77M | $-1.68M | $-1.58M | $-1.43M | $-1.32M | $-1.20M | $-1.20M |
High Forecast | $-658.97K | $-655.15K | $-651.37K | $-647.60K | $-32.27K | $-31.95K | $-31.63K | $-90.85K | $-98.79K | $-93.72K | $-113.96K | $-229.31K | $-911.78K | $-832.29K | $-659.43K | $-910.40K | $-1.69M | $-1.83M | $-1.55M | $-1.68M | $-1.51M | $-1.49M | $-1.77M | $-1.68M | $-1.58M | $-1.43M | $-1.32M | $-1.20M | $-1.18M |
Low Forecast | $-1.88M | $-1.87M | $-1.86M | $-1.85M | $-92.19K | $-91.27K | $-90.37K | $-93.03K | $-282.27K | $-267.76K | $-114.26K | $-229.43K | $-1.39M | $-2.38M | $-1.88M | $-2.60M | $-1.85M | $-1.83M | $-1.55M | $-1.68M | $-1.51M | $-1.49M | $-1.77M | $-1.68M | $-1.58M | $-1.43M | $-1.32M | $-1.20M | $-1.22M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.65% | 6.02% | 1.76% | 2.29% | 1.36% | 0.82% | 1.08% | 1.49% | 0.62% | 0.45% | 0.54% | 0.50% | 0.90% | 0.43% | 0.72% |
Forecast
Perspective Therapeutics Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-11.11M | $-371.00K | $-2.20M | $-3.93M | $-2.01M | $-1.21M | $-1.60M | $-2.24M | $-1.06M | $-745.00K | $-868.00K | $-713.00K | $-1.19M | $-545.00K | $-897.00K |
Avg Forecast | $-89.78M | $-86.97M | $-84.17M | $-84.17M | $-107.67M | $-101.05M | $-93.93M | $-86.29M | $-71.54M | $-59.86M | $-57.71M | $-78.56M | $-126.25M | $-84.17M | $334.51M | $-28.06M | $-21.04M | $-21.04M | $-28.06M | $-28.06M | $-28.06M | $-28.06M | $-28.06M | $-37.41M | $-37.41M | $-37.41M | $-46.76M | $-56.11M | $-5.61M |
High Forecast | $-33.14M | $-32.10M | $-31.07M | $-31.07M | $-39.74M | $-37.30M | $-34.67M | $-70.11M | $-54.37M | $-22.10M | $-21.30M | $-29.00M | $-46.60M | $-31.07M | $539.15M | $-10.36M | $-7.77M | $-21.04M | $-28.06M | $-28.06M | $-28.06M | $-28.06M | $-28.06M | $-37.41M | $-37.41M | $-37.41M | $-46.76M | $-56.11M | $-5.61M |
Low Forecast | $-144.70M | $-140.18M | $-135.66M | $-135.66M | $-173.54M | $-162.87M | $-151.39M | $-99.77M | $-82.98M | $-96.48M | $-93.02M | $-126.61M | $-203.49M | $-135.66M | $123.47M | $-45.22M | $-33.91M | $-21.04M | $-28.06M | $-28.06M | $-28.06M | $-28.06M | $-28.06M | $-37.41M | $-37.41M | $-37.41M | $-46.76M | $-56.11M | $-5.61M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.03% | 0.01% | 0.10% | 0.19% | 0.07% | 0.04% | 0.06% | 0.08% | 0.04% | 0.02% | 0.02% | 0.02% | 0.03% | 0.01% | 0.16% |
Forecast
Perspective Therapeutics SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $5.98M | $7.83M | $2.99M | $3.91M | $2.24M | $2.27M | $2.32M | $2.60M | $1.97M | $1.76M | $1.75M | $1.65M | $1.94M | $1.96M | $1.74M |
Avg Forecast | $2.18M | $2.17M | $2.16M | $2.14M | $106.83K | $105.78K | $104.73K | $156.69K | $327.12K | $310.31K | $194.47K | $390.90K | $1.96M | $2.76M | $2.18M | $3.01M | $3.01M | $3.13M | $2.63M | $2.86M | $2.57M | $2.54M | $3.02M | $2.86M | $2.69M | $2.44M | $2.24M | $2.05M | $2.05M |
High Forecast | $3.21M | $3.19M | $3.17M | $3.15M | $157.11K | $155.55K | $154.01K | $158.54K | $481.05K | $456.33K | $194.73K | $391.00K | $2.37M | $4.05M | $3.21M | $4.43M | $3.16M | $3.13M | $2.63M | $2.86M | $2.57M | $2.54M | $3.02M | $2.86M | $2.69M | $2.44M | $2.24M | $2.05M | $2.09M |
Low Forecast | $1.12M | $1.12M | $1.11M | $1.10M | $54.99K | $54.44K | $53.90K | $154.83K | $168.37K | $159.72K | $194.22K | $390.79K | $1.55M | $1.42M | $1.12M | $1.55M | $2.87M | $3.13M | $2.63M | $2.86M | $2.57M | $2.54M | $3.02M | $2.86M | $2.69M | $2.44M | $2.24M | $2.05M | $2.01M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.74% | 2.60% | 0.99% | 1.25% | 0.85% | 0.79% | 0.90% | 1.02% | 0.65% | 0.62% | 0.65% | 0.68% | 0.86% | 0.96% | 0.85% |
Forecast
Perspective Therapeutics EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 6 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.04 | $-0.00 | $-0.02 | $-0.03 | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.01 | $-0.01 |
Avg Forecast | $-0.32 | $-0.31 | $-0.30 | $-0.30 | $-0.38 | $-0.36 | $-0.33 | $-0.31 | $-0.25 | $-0.21 | $-0.21 | $-0.28 | $-0.45 | $-0.30 | $1.19 | $-0.10 | $-0.07 | $-0.07 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.13 | $-0.13 | $-0.13 | $-0.17 | $-0.20 | $-0.02 |
High Forecast | $-0.12 | $-0.11 | $-0.11 | $-0.11 | $-0.14 | $-0.13 | $-0.12 | $-0.25 | $-0.19 | $-0.08 | $-0.08 | $-0.10 | $-0.17 | $-0.11 | $1.92 | $-0.04 | $-0.03 | $-0.07 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.13 | $-0.13 | $-0.13 | $-0.17 | $-0.20 | $-0.02 |
Low Forecast | $-0.52 | $-0.50 | $-0.48 | $-0.48 | $-0.62 | $-0.58 | $-0.54 | $-0.36 | $-0.30 | $-0.34 | $-0.33 | $-0.45 | $-0.73 | $-0.48 | $0.44 | $-0.16 | $-0.12 | $-0.07 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.13 | $-0.13 | $-0.13 | $-0.17 | $-0.20 | $-0.02 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.03% | 0.02% | 0.21% | 0.37% | 0.14% | 0.09% | 0.11% | 0.16% | 0.07% | 0.05% | 0.08% | 0.08% | 0.10% | 0.04% | 0.66% |
Forecast
Perspective Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
CATX | Perspective Therapeutics | $6.78 | $18.00 | 165.49% | Buy |
SGHT | Sight Sciences | $3.77 | $9.00 | 138.73% | Hold |
LUNG | Pulmonx | $6.00 | $11.93 | 98.83% | Buy |
HYPR | Hyperfine | $0.87 | $1.60 | 83.91% | Buy |
KIDS | OrthoPediatrics | $24.32 | $39.60 | 62.83% | Buy |
SIBN | SI-BONE | $12.32 | $20.00 | 62.34% | Buy |
NPCE | NeuroPace | $9.18 | $12.88 | 40.31% | Buy |
LIVN | LivaNova | $51.36 | $70.50 | 37.27% | Buy |
OFIX | Orthofix Medical | $18.73 | $24.00 | 28.14% | - |
CVRX | CVRx | $13.42 | $16.33 | 21.68% | Buy |
FNA | Paragon 28 | $10.50 | $11.50 | 9.52% | Buy |
SRDX | Surmodics | $39.19 | $39.50 | 0.79% | Buy |